Industry Briefs: Jan. 30, 2012

A roundup of other company and people news from pharmaceutical and biopharmaceutical companies, their suppliers, and contract-service providers.

Company News

Aptar Pharma has opened a new manufacturing site near Mumbai, India. Read More

FDA has approved Pfizer’s Inlyta (axitinib), a kinase inhibitor for treating advanced renal cell carcinoma. Read More

FDA has approved Roche’s Erivedge (vismodegib) capsule for treating advanced basal cell carcinoma. Read More

Lpath has temporarily suspended dosing of iSONEP, for treating age-related macular degeneration, in clinical trials due to cGMP compliance issues at the contract fill–finish source. Read More

Roche has formally issued an offer to acquire all outstanding shares of Illumina for $44.50 per share in cash, or an aggregate of approximately $5.7 billion. Read More

Royal DSM and Indoco Remedies have formed a commercialization agreement for eight APIs. Read More

Valeant Pharmaceuticals has withdrawn its offer to acquire ISTA Pharmaceuticals for $7.50 per share in cash. Read More

Watson Pharmaceuticals announced plans to establish a New Jersey-based R&D technology center to support generic-drug pharmaceutical product development. Read More

People News

GlaxoSmithKline has announced changes to its board of directors. Read More

Octagon Research Solutions has appointed Gina L. Schmidt to manage the company’s global regulatory services division. Read More